Racial and ethnic differences in the metabolic response of polycystic ovary syndrome

2020 ◽  
Vol 93 (2) ◽  
pp. 163-172 ◽  
Author(s):  
Uche Ezeh ◽  
Yii‐Der Ida Chen ◽  
Ricardo Azziz
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ethnic Differences ◽  
Metabolic Response ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Racial And Ethnic Differences

scholarly journals Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype

2017 ◽  
Vol 216 (5) ◽  
pp. 493.e1-493.e13 ◽  
Author(s):  
Lawrence Engmann ◽  
Susan Jin ◽  
Fangbai Sun ◽  
Richard S. Legro ◽  
Alex J. Polotsky ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ethnic Differences ◽  
Polycystic Ovary ◽  
Metabolic Phenotype ◽  
Ovary Syndrome ◽  
Racial And Ethnic Differences

scholarly journals RACIAL AND ETHNIC DIFFERENCES IN THE PREVALENCE OF DIAGNOSED POLYCYSTIC OVARY SYNDROME IN WOMEN RECEIVING AMBULATORY CARE

2020 ◽  
Vol 114 (3) ◽  
pp. e402-e403
Author(s):  
Olumayowa M. Dayo ◽  
Nancy P. Gordon ◽  
Malini Chandra ◽  
Miranda L. Weintraub ◽  
Joan C. Lo
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ambulatory Care ◽  
Ethnic Differences ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Racial And Ethnic Differences

Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

2015 ◽  
Vol 82 (6) ◽  
pp. 885-891 ◽  
Author(s):  
Mehri Jamilian ◽  
Maryamalsadat Razavi ◽  
Zohreh Fakhrie Kashan ◽  
Yasser Ghandi ◽  
Tayebeh Bagherian ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Metabolic Response ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Selenium Supplementation ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome

2018 ◽  
Vol 1 (1) ◽  
pp. 24-33 ◽  
Author(s):  
Monika Sarkar ◽  
Norah Terrault ◽  
Caroline C DUWAERTS ◽  
Phyllis Tien ◽  
Marcelle Cedars ◽  
...  
Keyword(s):  
Liver Disease ◽  
Polycystic Ovary Syndrome ◽  
Hepatic Steatosis ◽  
Ethnic Differences ◽  
Fatty Liver Disease ◽  
Polycystic Ovary ◽  
Hispanic Women ◽  
Ovary Syndrome ◽  
Nonalcoholic Fatty Liver ◽  
Hispanic Ethnicity

Polycystic Ovary Syndrome (PCOS) affects 10-15% of reproductive age women and is a recognized risk factor for hepatic steatosis, a form of nonalcoholic fatty liver disease (NAFLD). The more severe form of NAFLD, known as nonalcoholic steatohepatitis (NASH), results in liver inflammation, and is now a leading cause of cirrhosis. Ethnic differences are apparent in NAFLD, with higher prevalence in Hispanics, although the role of Hispanic ethnicity on risk for NAFLD/NASH in women with PCOS is not known. Objective: The aim of this study was to evaluate ethnic differences in the prevalence and risk of NAFLD in women with PCOS. Study Design: Among PCOS women followed in a large academic medical center the association of Hispanic ethnicity with elevated biomarkers of NASH, including plasma cytokeratin 18 (CK18) M30 fragments and/or ALT levels (n=303), was assessed. Prevalence of hepatic steatosis by Controlled Attenuation Parameter (CAP) imaging was evaluated in a subset of PCOS women (n=35). Results: The median cohort age (n=303) was 28 years (IQR 8), and 15.5% (n=47) were Hispanic, the majority of whom reported white race (94%). Most Hispanic women had hepatic steatosis on imaging, which was markedly higher than in non-Hispanics (83% vs 24%, p=0.005). Approximately 17% of PCOS women had elevated ALT or elevated CK18, which was more common in Hispanics than non-Hispanics, at 34% vs 14%, respectively, p=0.002. On univariate analysis, Hispanic ethnicity was associated with two-fold higher odds of NASH (OR 2.0, 95% CI 1.0-3.9, p=0.038), and the association persisted after adjustment for HOMA-IR and waist circumference (AOR 3.1, 95% CI 1.1-8.9, p=0.034). Conclusion: NAFLD/NASH is an important condition to be considered by PCOS providers and Hispanic women with PCOS are a particularly high-risk group that may warrant routine screening.

scholarly journals Association between Polymorphisms of OCT1 and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome

2019 ◽  
Vol 20 (7) ◽  
pp. 1720 ◽  
Author(s):  
Hui Chang ◽  
Yuan-Shuo Hsueh ◽  
Yung Cheng ◽  
Huang-Tz Ou ◽  
Meng-Hsing Wu
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Treatment Effectiveness ◽  
Metabolic Response ◽  
Polycystic Ovary ◽  
Organic Cation Transporter ◽  
Oral Glucose ◽  
Metformin Treatment ◽  
Nucleotide Polymorphisms ◽  
Ovary Syndrome ◽  
Insulin Sensitizer

Insulin-sensitizer treatment with metformin is widely used in polycystic ovary syndrome (PCOS). However, the treatment effectiveness shows individual differences in PCOS patients. Organic cation transporter (OCT) 1 and 2 have been reported to mediate metformin transport in the liver and kidney, respectively. In this study, we investigated the association between the polymorphisms of OCT1 and OCT2 and the treatment effectiveness of metformin in PCOS patients. The single nucleotide polymorphisms (SNPs) of OCT1 (rs683369 and rs628031) and OCT2 (rs316019) were analyzed in 87 PCOS and 113 control women. Oral glucose tolerance tests (OGTTs), which represented metformin treatment response, were conducted at the start of treatment and after six-month treatment. The results demonstrated that the SNP frequencies of OCT1 and OCT2 were not associated with PCOS pathophysiology, and that the polymorphisms of OCT1 and OCT2 were not associated with the OGTT parameters at baseline. However, PCOS patients with the G allele of OCT1 rs683369 and/or with the A allele of OCT1 rs628031 had increased insulin sensitivity compared to those with wild-type genotype after receiving metformin treatment. Moreover, the interactions of metformin*SNP were significant in both OCT1 rs683369 (p < 0.001) and rs628031 (p = 0.001) during the treatment period. Taken together, genetic polymorphisms of OCT1 contributed to different metformin treatment responses, and further study is needed to establish personalized treatment programs using a pharmacogenomic algorithm approach in PCOS patients.

Sign in / Sign up

Export Citation Format

Share Document